Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$1.06
At close: May 28 EDT
$1.01
-0.05-4.72%
Pre-Market: 9:28 AM EDT
Comments
Loading...
Quince Therapeutics Analyst Ratings and Price Targets | NASDAQ:QNCX | Benzinga
Quince Therapeutics Inc has a consensus price target of $8.67 based on the ratings of 6 analysts. The high is $12 issued by EF Hutton on October 22, 2024. The low is $4 issued by D. Boral Capital on March 25, 2025. The 3 most-recent analyst ratings were released by D. Boral Capital, Oppenheimer, and D. Boral Capital on March 25, 2025, March 24, 2025, and February 5, 2025, respectively. With an average price target of $8.67 between D. Boral Capital, Oppenheimer, and D. Boral Capital, there's an implied 758.09% upside for Quince Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
D. Boral Capital
Oppenheimer
Brookline Capital
Maxim Group
Rodman & Renshaw
1calculated from analyst ratings
Analyst Ratings for Quince Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 03/25/2025 | Buy Now | 296.04% | D. Boral Capital | Jason Kolbert43% | $12 → $4 | Maintains | Buy | Get Alert |
| 03/24/2025 | Buy Now | 890.1% | Oppenheimer | Leland Gershell67% | → $10 | Initiates | → Outperform | Get Alert |
| 02/05/2025 | Buy Now | 1088.12% | D. Boral Capital | Jason Kolbert43% | $12 → $12 | Maintains | Buy | Get Alert |
| 01/02/2025 | Buy Now | 1088.12% | D. Boral Capital | Jason Kolbert43% | $12 → $12 | Maintains | Buy | Get Alert |
| 12/18/2024 | Buy Now | 791.09% | Brookline Capital | Kumaraguru Raja22% | → $9 | Initiates | → Buy | Get Alert |
| 11/14/2024 | Buy Now | 1088.12% | D. Boral Capital | Jason Kolbert43% | $12 → $12 | Maintains | Buy | Get Alert |
| 11/12/2024 | Buy Now | 1088.12% | D. Boral Capital | Jason Kolbert43% | $12 → $12 | Maintains | Buy | Get Alert |
| 11/07/2024 | Buy Now | 494.06% | Maxim Group | Jason McCarthy42% | → $6 | Initiates | → Buy | Get Alert |
| 10/29/2024 | Buy Now | 989.11% | Rodman & Renshaw | Elemer Piros53% | → $11 | Initiates | → Buy | Get Alert |
| 10/22/2024 | Buy Now | 1088.12% | EF Hutton | Jason Kolbert43% | → $12 | Initiates | → Buy | Get Alert |
FAQ
What is the target price for Quince Therapeutics (QNCX) stock?
The latest price target for Quince Therapeutics (NASDAQ:QNCX) was reported by D. Boral Capital on March 25, 2025. The analyst firm set a price target for $4.00 expecting QNCX to rise to within 12 months (a possible 296.04% upside). 10 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Quince Therapeutics (QNCX)?
The latest analyst rating for Quince Therapeutics (NASDAQ:QNCX) was provided by D. Boral Capital, and Quince Therapeutics maintained their buy rating.
When was the last upgrade for Quince Therapeutics (QNCX)?
There is no last upgrade for Quince Therapeutics
When was the last downgrade for Quince Therapeutics (QNCX)?
There is no last downgrade for Quince Therapeutics.
When is the next analyst rating going to be posted or updated for Quince Therapeutics (QNCX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Quince Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Quince Therapeutics was filed on March 25, 2025 so you should expect the next rating to be made available sometime around March 25, 2026.
Is the Analyst Rating Quince Therapeutics (QNCX) correct?
While ratings are subjective and will change, the latest Quince Therapeutics (QNCX) rating was a maintained with a price target of $12.00 to $4.00. The current price Quince Therapeutics (QNCX) is trading at is $1.01, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
